St. Jude trial identifies a medulloblastoma subset that requires less aggressive therapy

St. Jude Children’s Research Hospital researchers have identified a subtype of the brain tumour medulloblastoma that is associated with improved survival of infants treated with less aggressive, risk-adapted therapy. The report appears today in the journal Lancet Oncology and sets the stage for screening medulloblastoma patients to identify those with the subtype.